Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anhydrous citric acid + gluconolactone + magnesium carbonate is a **small molecule combination irrigation solution** marketed as **Renacidin** for urological use. It is a sterile, non-pyrogenic solution indicated for dissolution of **struvite** and **apatite bladder calculi** by local intermittent irrigation through a urethral catheter or cystostomy tube, and for **prevention of encrustations** of urethral catheters and cystostomy tubes. Its effect is mediated by a **chemical dissolution mechanism rather than a specific biological receptor target**: the acidic solution helps solubilize struvite calculi, while magnesium in the solution exchanges with calcium in apatite stones to form more soluble magnesium salts. It has also been used as adjunctive therapy to help dissolve residual calculi after surgery or facilitate removal of renal calculi. The product is manufactured by United-Guardian.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anhydrous citric acid + gluconolactone + magnesium carbonate.